NCT06520189Not yet recruiting
Value of F-18 FDG PET/CT for the Prediction of EGFR Mutation in Lung Cancer Patients
Source: ClinicalTrials.gov · Last updated 25 Jul 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To detect value of F-18FDG PET/CT as a non-invasive method for the prediction of EGFR mutations in lung cancer patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 20 Jul 2024
- Start date
- Oct 2024
- Primary completion date
- Oct 2028
- Lead sponsor
- Assiut University
- Diseases
- Lung cancer
- NCT number
- NCT06520189
What you commit to
- Study type: Observational
- Planned participants: 60
- From Oct 2024 to the primary completion date, Oct 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Time interval between EGFR sampling and PET/CT more than 1 month.
- Patients with glucose level \< 200 mg/dl.
Other
- Patients had been treated before sampling for the gene alteration analysis
Who the study is looking for
- NSCLC patients who underwent EGFR mutation testing.
- All patients ≥ 18 years.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.